medigraphic.com
SPANISH

Revista Médica MD

  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2015, Number 1

<< Back Next >>

Rev Med MD 2015; 6.7 (1)

Lesiones en sacabocados en Mieloma Múltiple

Herrera-Aguilar FE, Venegas-Ponce GA, Zamora-Díaz D
Full text How to cite this article

Language: Spanish
References: 16
Page: 64-65
PDF size: 478.52 Kb.


Key words:

No keywords

Text Extraction

No abstract.


REFERENCES

  1. 1.Antonio Palumbo, M.D., and Kenneth Anderson. Multiple Myeloma. N Engl J Med 2011;364:1046- 60

  2. 2.ChristophRöllig, Stefan Knop, Mar tin Bornhäuser. Multiple mieloma. Lancet 2015; 385: 2197–208

  3. 3 .Terpos E, Dimopoulos M A. Myelomabonedisease: pathophysiologyand management. Ann Oncol 2005; 16: 1223–1231

  4. 4.Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri Aet al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo ClinProc 2003; 78: 21–33

  5. 5 . Callander N S, Roodman G D. Myelomabonedisease. Semin Hematol 2001; 38: 276–285

  6. 6.Raje N, Anderson KC. Multiplemyeloma. Curr Treat Options Oncol 2000; 1: 73–82

  7. 7.Epstein J, Walker R. Myeloma and bonedisease: ''the dangerous tango''. Clin Adv Hematol Oncol 2006; 4: 300–306

  8. 8.Giuliani N, Rizzoli V, Roodman GD. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 2006;108: 3992–3996

  9. 9.Terpos E, Sezer O, Croucher P, Dimopoulos MA. Myeloma bone disease and proteasome inhibition therapies. Blood 2007; 110: 1098–1104

  10. 10.Boccadoro M, Pileri A. Plasma cell dyscrasias: classification, clinical and laboratory characteristics, and differential diagnosis. Baillieres Clin Haematol 1995; 8: 705–719

  11. 11.Chassang M, Grimaud A, Cucchi JM, Novellas S, Amoretti N,Chevallier P et al. Can low-dose computed tomographic scan of the spine replace conventional radiography? An evaluation based on imaging myelomas, bone metastases, and fractures from osteoporosis.Clin Imaging 2007; 31: 225 –227

  12. 12.Collins CD. Multiplemyeloma. Cancer Imaging 2004; 4 (Spec NoA): S47–S53.

  13. 13.Dimopoulos MA, Moulopoulos A, Smith T, Delasalle KB,Alexanian R. Risk of disease progression in asymptomatic multiple myeloma. Am J Med 1993; 94: 57–61

  14. 14.Wisløff F, Andersen P, Andersson TR, Brandt E, Eika C, Fjaestad Ket al. Incidence and follow-up of asymptomaticmultiplemyeloma. The myeloma project of health region I in NorwayII. Eur J Haematol 1991; 47: 338–341.

  15. 15.International MyelomaWorkingGroup. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International MyelomaWorking Group.Br J Haematol 2003; 121: 749–757.

  16. 16.M Dimopoulos1, E Terpos. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia (2009) 23, 1545–1556




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Rev Med MD. 2015;6.7